✨ Free AI Report
Leap Therapeutics, Inc. (now Cypherpunk Technologies Inc.): Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Leap Therapeutics, Inc. (now Cypherpunk Technologies Inc.)
Company Research

Leap Therapeutics, Inc. (now Cypherpunk Technologies Inc.): Business Overview, Financials & Competitive Analysis

Leap Therapeutics is focused on developing targeted and immuno-oncology therapeutics, with its most advanced clinical candidate being DKN-01 (sirexatamab), a humanized monoclonal antibody targeting the Dickkopf-1 (DKK...

Analyst-debate audio for Leap Therapeutics, Inc. (now Cypherpunk Technologies Inc.)

AskCyborg analysts argue the bull and bear cases for Leap Therapeutics, Inc. (now Cypherpunk Technologies Inc.) across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
4/ 10Mixed

Cyborg Score thesis

Clinical-stage micro-cap biotech with promising monoclonal antibody candidates facing high execution risk and funding dependency...

Read the full analyst-debate transcript →
Industry Biopharmaceutical / Oncology Therapeutics
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Leap Therapeutics, Inc. (now Cypherpunk Technologies Inc.) Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Leap Therapeutics, Inc. (now Cypherpunk Technologies Inc.) Overview

Pro stress-test →

Leap Therapeutics is focused on developing targeted and immuno-oncology therapeutics, with its most advanced clinical candidate being DKN-01 (sirexatamab), a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein being developed in patients with esophagogastric, gynecologic, and colorectal cancers. In November 2025, the company rebranded to Cypherpunk Technologies Inc. and began trading under the ticker CYPH while continuing cancer drug development through a subsidiary carrying the Leap Therapeutics name.

Strategic Profile

Pro stress-test →

The company completed a $58.88 million private placement in October 2025 and deployed approximately $50 million to acquire Zcash (ZEC) as part of a new digital asset treasury strategy alongside its oncology pipeline. Leap showcases a strong clinical outlook with sirexatamab demonstrating a notable 39% objective response rate in patients with elevated DKK1 levels, positioning the company to engage with the FDA for potential regulatory pathway advancement.

Competitive Landscape

Pro stress-test →

Leap operates in the targeted and immuno-oncology therapeutics space, competing against larger established players in monoclonal antibody development for solid tumors. The company's differentiation relies on specific DKK1 and Claudin18.2 targeting mechanisms with early clinical data, but faces intense competition from well-capitalized oncology biotech firms and Big Pharma programs in similar indications.

Industry Context

Leap Therapeutics, Inc. (now Cypherpunk Technologies Inc.) operates in Biopharmaceutical / Oncology Therapeutics.

Key facts

Founded: 2011 · Headquarters: Cambridge, Massachusetts · Market cap: $24.8M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Leap Therapeutics, Inc. (now Cypherpunk Technologies Inc.).

  • DKN-01 demonstrates 38% response rate in DKK1-high colorectal cancer populations versus 23.7% in controls, with potential for FDA regulatory engagement
  • FL-501 (GDF-15 targeting antibody) planned for clinical trial entry in 2026 to address cancer cachexia, a condition lacking effective treatments
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • November 2025Rebranded to Cypherpunk Technologies; completed $58.88M private placement; acquired $50M in Zcash (ZEC)
  • October 2025Private placement led by Winklevoss Capital to fund operations and digital asset treasury strategy
  • +1 moreTrack every material event for Leap Therapeutics, Inc. (now Cypherpunk Technologies Inc.) as it happens. Explore monitoring →
Get alerted when Leap Therapeutics, Inc. (now Cypherpunk Technologies Inc.) has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Claudin18.2-targeted therapeuticsCompeting gastric/pancreatic cancer antibody programs→DKK1-pathway inhibitionLarge pharma exploring similar Wnt pathway targets→Immuno-oncology monoclonal antibodiesEstablished competitors in cancer immunotherapy space→

Compare Leap Therapeutics, Inc. (now Cypherpunk Technologies Inc.) with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Leap Therapeutics, Inc. (now Cypherpunk Technologies Inc.) operates in Biopharmaceutical / Oncology Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceutical by Cyborg Score

Browse Biopharmaceutical / Oncology Therapeutics research →
NEW · MCP server

Ask your AI assistant about Leap Therapeutics, Inc. (now Cypherpunk Technologies Inc.)

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Leap Therapeutics, Inc. (now Cypherpunk Technologies Inc.) and its top competitor on Cyborg Score”
“What did Leap Therapeutics, Inc. (now Cypherpunk Technologies Inc.) do this quarter?”
“Is Leap Therapeutics, Inc. (now Cypherpunk Technologies Inc.) a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Leap Therapeutics, Inc. (now Cypherpunk Technologies Inc.) do?+
Leap Therapeutics is focused on developing targeted and immuno-oncology therapeutics, with its most advanced clinical candidate being DKN-01 (sirexatamab), a humanized monoclonal antibody targeting the Dickkopf-1 (DKK...
What is Leap Therapeutics, Inc. (now Cypherpunk Technologies Inc.)'s Cyborg Score?+
Leap Therapeutics, Inc. (now Cypherpunk Technologies Inc.) has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Leap Therapeutics, Inc. (now Cypherpunk Technologies Inc.)'s main competitors?+
Named competitors include Claudin18.2-targeted therapeutics, DKK1-pathway inhibition, Immuno-oncology monoclonal antibodies. The full competitive landscape is in the AskCyborg report.
How can I get the full Leap Therapeutics, Inc. (now Cypherpunk Technologies Inc.) research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Leap Therapeutics, Inc. (now Cypherpunk Technologies Inc.) research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Leap Therapeutics, Inc. (now Cypherpunk Technologies Inc.) over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical research

Companies in the same sector and named competitors, ranked by Cyborg Score.

9Eli Lilly and Company8argenx SE8Ascendis Pharma A/S8Avidity Biosciences, Inc.8BeOne Medicines AG8Celltrion, Inc.8Corcept Therapeutics Incorporated8Insmed Incorporated8Roivant Sciences Ltd.8Terns Pharmaceuticals, Inc.Top companies in Biopharmaceutical by Cyborg Score